Navigation Links
Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
Date:5/3/2010

RYE, N.Y., May 3 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Keystone Symposia meeting, Toward Defining the Pathophysiology of Autistic Behavior, held in April in Snowbird, Utah.  

Fallon presented on "The Role of Protein Assimilation and Utilization in Children with Autism."  She discussed Curemark's research exploring a possible link between a lack of protein-digesting enzymes in autistic children, necessary for the production of amino acids needed for brain function, and the symptoms of autism.  

"The Keystone Symposia meeting provided an excellent forum to share our research with others in the scientific community who are attempting to understand the physiological causes of autism and working to develop possible therapies," Fallon said.

Curemark is in the midst of Phase III clinical trials for CM-AT, its autism treatment targeted as enzyme replacement therapy.  CM-AT recently was designated as a Fast Track drug by the FDA.

Keystone Symposia on Molecular and Cellular Biology is a non-profit organization with a 38-year history of organizing conferences to connect the scientific community and accelerate scientific discoveries.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
2. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
3. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
4. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Announces Senior Executive Promotions
7. Curemark CEO Presents at Epigenomics Conference
8. Curemark Closes Series A Financing
9. Curemark Appoints Preeminent Pediatrics Gastroenterologist
10. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
11. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27, 2017 Amarantus ... BioMedical assets for potential acquisition ... contemplates capital infusion into Amarantus to assist in restructuring ... Amarantus names four new appointees to its Board of Directors and names ... Biomedical Inc. (SeD Biomedical) , a Singapore ...
(Date:2/28/2017)... The global  pulse oximeters market  is expected to reach USD 2.8 billion by ... oximeters market is anticipated to witness significant growth during the forecast period, which ... obstructive pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic conditions. ... ... Grand View Research Logo ...
(Date:2/28/2017)... 28, 2017 Nordic Nanovector ASA (OSE: NANO) announces ... presentation of the results by the company,s senior management team will ... - details below. ... 2016 was a very successful year for Nordic Nanovector. ... Betalutin®, progressed with our preclinical candidates and build the foundation of ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed ... that despite scientific studies, the Center for Disease Control ( CDC ) and Infectious ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument ...
(Date:2/27/2017)... ... 27, 2017 , ... Silicon Valley Hair Institute, a professional ... informational post on robotic hair transplantation. San Francisco residents may be confused over ... Unit Transplantation (FUT) can sound similar. Either treatment can be used to provide ...
(Date:2/26/2017)... ... , ... The February 13, 2017, assassination of Kim Jong-nam, the half brother ... the deadly use of chemical weapons. Many questions exist about the effect that nerve ... be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and one of ...
(Date:2/26/2017)... CA (PRWEB) , ... February 26, 2017 , ... NuevaCare, ... cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an ... Many Bay Area consumers look for home care close to home, and by having ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable ... entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects ...
Breaking Medicine News(10 mins):